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Background: A need for a governance of genomics in healthcare among European Union (EU) countries arose
during an international meeting of experts on public health genomics (PHG). We have conducted a survey on
existing national genomic policies in healthcare among Chief Medical Officers (CMOs) of the 28 EU member states,
plus Norway. Methods: A questionnaire was sent to CMOs after a meeting on the policy implications of PHG held
during the Italian presidency of the Council of EU in 2014. The survey was closed in November 2015. Results: CMOs
response rate was 65.5% (19/29). Twelve (63.2%) reported that their countries had a policy for genomics in
healthcare in place, and 15 (78.9%) reported that public funding existed. Public research facilities for the devel-
opment of such policies were documented in 13 (68.4%) countries, and 15 (83.3%) had working groups devoted to
policy development. National agencies carrying out Health Technology Assessment of genomic-based technologies
were present in nine countries (50%). Sixteen (88.9%) countries reported having agencies dealing with ethical
issues related to genomic technologies. About 55% of countries disclosed the lack of information campaigns
aimed at citizens, and 44.4% reported they had a legal framework for direct-to-consumer genetic tests.
Conclusion: Belgium, France, Italy, Spain and UK documented the presence of a policy on genomics in
healthcare. While many caveats are necessary because of the methodology, results suggest a need for a co-
ordinated effort to foster development and harmonization of dedicated policies across EU to responsibly
integrate genomics policies into existing health systems.
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Introduction
Advances in genomics have important implications for publichealth, for example by offering new ways of differentiating in-
dividuals and groups within populations according to their suscep-
tibility to disease or ability to benefit from treatment.1,2 Yet, despite
rapidly advancing genomic technologies, these have, to date,
received limited attention in debates on health policy.
Since 2005, a multidisciplinary group has been assessing the potential
implications of genomic developments for population health, leading
to the term ‘‘Public Health Genomics’’ (PHG), defined as ‘‘the respon-
sible and effective translation of genome-based knowledge and technologies
into public policy and health services for the benefit of population health.3
In 2014, an international meeting of experts recognised the urgent need
for the public health community (with its focus on population-based
prevention) to engage with scientists and clinicians (with their primary
focus on the individual and his or her genes) in order to maximise the
potential that genomics offers for effective and equitable disease
prevention and health improvement.4
Seeking to engage policy makers in this discussion, the Italian
Ministry of Health organized a meeting in Rome in October 2014,
during the Italian presidency of the Council of the European Union.
The 28 Chief Medical Officers (CMO) of EU member states, plus the
CMO from Norway, were invited to discuss the policy implications
of advancements in genomics for health systems.5 The meeting
concluded with a call for coordinated engagement to develop
policy on genomics in healthcare within the EU. To inform this
process, we undertook a survey of EU CMOs, including both
those present at the meeting and those unable to participate.
Methods
The survey draws on an earlier one undertaken in 2013 by the Italian
Ministry of Health looking at the policies and practice relating to
genomics in healthcare in EU member states, in collaboration with
the Federation of European Academies of Medicine (FEAM).6 In the
present survey, W.M. and S.B. designed a structured questionnaire,
containing 22 questions organized into seven sections (A–G,
table 1). Section A asks about the presence, and extent, of any
policy on genomics in healthcare and related financial support.
Section B examines research in support of genomics policy in
healthcare. Section C examines progress in developing genomics in
healthcare. Section D asks about health technology assessment while
Sections E, F and G exploring ethical and legal issues, education and
training, and public engagement, respectively.
The 22 CMOs participating in the meeting (Croatia, Cyprus, Czech
Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland,
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Table 1 The questionnaire with twenty-two questions organized into seven sections (A–G)
Section Question Sub-question (where applicable)
A. Policy A1.a Is there a policy concerning the use of genomics in healthcare or
health services in place in your country?
A1.b If yes, are there any specific guidelines already in
place in your country?
A2.a Does your country provide any kind of support for the development
of policy concerning the use of genomics in healthcare or health
services?
A2.b If yes, please provide further details about the
Institutions providing support
[Selection Public and Private institutions]
A3. Do you know how much of the public funding during the last calendar
year was devoted to the development of policy concerning the use of
genomics in healthcare or health services?
(< E50 000, E50 000–200 000, E>200 000, I am not aware/not certain)
A4. Do you know how much of the private funding during the last
calendar year was devoted to the development of policy concerning the
use of genomics in healthcare or health services?
(< E50 000, E50 000–200.000, E>200 000, I am not aware/not certain)
B. Research B1.a Do research facilities exist in your country devoted to the develop-
ment of policy or service in the use of genomics in healthcare?
B1.b If yes, public or private?
B2.a Is/Are there in your country Institution/s providing financial support to
the research in policy or service development in the use of genomics in
healthcare?
B2.b If yes, please provide further details about the
Institutions providing support.
[Selection of Public and Private institutions]
B3. Do you know of any research projects on policy or service development
in the use of genomics in healthcare in your country, supported by
public funding?
B4. Do you know of any research projects on policy or service development




C1.a Have PHG progress reports ever been published in your country? C1.b If yes, whom are they addressed to?
[Selection of stakeholders]
C2. Who has developed and published those progress reports?
(Universities, Ministry, I am not aware/not certain, Others)
C3. Are reports regularly developed?
(No, Less than once a year, At least once a year)
C4. Could you provide information about the most recently published
report? (title, authors, publication year), link(s) to the web page(s), and
the institutions providing them
D. Technical
Facilities
D1. Are there national groups (agencies, technical/professional working
groups, commissions, etc.) working on policy or service development in
the use of genomics in healthcare in your country?
D2. Are there national agencies carrying out national Health Technology
Assessment and/or horizon scanning on genome-based technologies in
your country?
D3. Are there regional groups (agencies, technical/professional working
groups, commissions, etc.) dealing with policy or service development in
the use of genomics in healthcare in your country?
D4. Are there regional agencies carrying out the National Health
Technology Assessment and/or horizon scanning on genome-based
technologies in your country?
E. Ethical
Implications
E1. Are you aware about the existence of departments/agencies at the
national or regional level discussing the ethical issues and/or legal
matters related to the use of genomics in healthcare in your country?
E2. Are you aware about the existence of departments/agencies at the
national or regional level whose expertise might be included in the
discussion of ethical issues and/or legal matters related to policy or




F1. Do you know if the issues surrounding the use of genomics in
healthcare are taught in health-related university courses, either in the
form of seminars, teaching modules or as a specific subject, in your
country?
(Yes, in pre-graduate courses, Yes, in post-graduate courses, No)
F2.a Are specific training courses available for health professionals with
particular regard to the correct use and proper prescription of suscep-
tibility testinga (for complex disorders) in your country?
F2.b If yes, for which professional categories are they
addressed to?
[Selection of professional categories]
G. Citizens G1. Has your country ever established information campaigns (advertising
on billboards, campaigns, commercials, TV or radio, etc.) on suscepti-
bility tests (for complex disorders)?
G2. Has your country adopted a legal framework, professional and other
guidelines or developed ethical opinions for the use of Direct-to-
Consumer Genetic Tests?
a: Susceptibility testing (also known as predisposition test) detects genetic variants that are associated with an increased risk of disease but
cannot predict with certainty the development of disease, because of the incomplete penetrance of the genetic mutation.
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Italy, Latvia, Lithuania, Luxembourg, The Netherlands, Norway,
Poland, Portugal, Slovenia, Spain, Sweden and UK), plus 7 (Austria,
Belgium, Bulgaria, Germany, Malta, Romania and Slovakia) that were
not present at the Rome meeting, were contacted electronically by the
Italian Ministry of Health with a link to the online questionnaire. The
cover letter defined public health genomics, using the earlier Bellagio
Statement.3 Respondents were asked to nominate alternatives if they
were unable to complete the survey.
Three reminders were made by e-mail. Entries were accepted until
November 2015. Respondents were able to attach documents or
include hyperlinks to relevant material. Simple tabulations of
responses were undertaken, using the number of countries
responding as the denominator.
Results
The response rate was 65.5% (19/29 of the CMOs), although one
(Ireland) completed only the first two sections of the questionnaire.
Table S1 (Supplementary materials) lists the countries that
participated in the survey and the date of the questionnaires’
submission. Table S2 shows the tabulations of answers by Country
for the closed-ended questions.
Table 2 presents responses to each of the 22 survey questions,
apart from those relating to public and private funding sources for
policies on genomics in healthcare and for research supporting these
policies, which are presented in tables 3 and 4, respectively. Results
are reported according to the seven sections of the questionnaire.
Section A: policies in place and financial
support for policy development
Twelve (63.2%) countries (Austria, Belgium, Estonia, France,
Hungary, Italy, Latvia, Norway, Poland, Spain, The Netherlands
and the UK) reported having a policy on genomics in healthcare
in place, and, out of these countries, 10 (83.3%) (Austria, Belgium,
Estonia, France, Hungary, Italy, Poland, Spain, The Netherlands and
the UK) documented the presence of specific guidelines (table 2).
Fifteen (78.9%) countries (Austria, Belgium, Croatia, Estonia,
Finland, France, Hungary, Italy, Malta, Norway, Poland, Slovenia,
Spain, The Netherlands and the UK) reported having dedicated
funding for development of policies on genomics in healthcare. Of
these, all reported that the support was provided by public institu-
tions (table 3). Six countries (40.0%) reported public funding from
the Ministry of Research, 14 (93.3%) from the Ministry of Health, 3
(20.0%) from other Ministries and 10 (66.7%) from other public
sources. The sums involved ranged from around E50 000/year (four
countries, 26.7%) reported a public spending of around E50 000/
year (Austria, Finland, Malta, Slovenia), >E200 000/year (6
countries, 40.0%, Belgium, Italy, Poland, Spain, The Netherlands
and UK), while respondents from the remaining five countries
(33.3%) were unable to give a precise figure.
Of the 15 countries reporting funding for the development of
genomics policy in healthcare, five (33.3%, Belgium, Estonia,
France, Norway and Spain) reported additional private sources of
funding. These were mostly from the pharmaceutical industry
(40.0%), private research institutes (60.0%) and other private
sources (60.0%). Only two countries (Belgium and Spain) were
able to report the amount of private funding, with both document-
ing an amount of >E200 000/year.
Section B: research in support of policy of
genomics in healthcare
Thirteen (68.4%) of the countries (Belgium, Croatia, Estonia, France,
Hungary, Italy, Latvia, Norway, Poland, Portugal, Slovenia, Spain and
the UK) reported having public research facilities devoted to devel-
opment of policy or services in genomics. Among these countries,
Hungary, Spain and the UK (23.1%) reported having additional
private institutions devoted to such research (data not shown).
Fourteen (73.7%) countries (Austria, Belgium, Croatia, Estonia,
Finland, France, Italy, Latvia, Norway, Poland, Portugal, Slovenia,
Spain and the UK) documented funding from public institutions for
research on development of genomics policy in healthcare (table 2).
Of these countries, 78.6% identified the Ministry of Health as the
source of the public funding, 21.4% the Ministry of Research, 21.4%
other ministries and 28.6% other public institutions (table 4). No
country reported financial support from private institutions for the
development of policies on genomics in healthcare.
Lastly, 12 respondents (63.2%) (Austria, Belgium, Estonia,
Finland, France, Hungary, Italy, Latvia, Poland, Spain, The
Netherlands and the UK) reported undertaking research projects
on policy or service development supported by public funding,
while 10.5% (Hungary and The Netherlands) were aware of
private funding dedicated to policy research (table 2).
Section C: progress report
Nine countries (50.0%) (Austria, Belgium, Estonia, Italy, Latvia,
Norway, Spain, The Netherlands and the UK) reported that
national reports on progress in public health genomics were
published (table 2). All were addressed to decision-makers, 66.7%
Table 2 Answers to the survey questions according to the A–G sections
Questionnaire section Question no. No. of responding countries Yes (%) No (%) Not aware (%)
A. Policy A1.a 19 12 (63.2) 7 (36.8) 0 (0.0)
A1.b 12 10 (83.3) 2 (16.7) 0 (0.0)
A2.a 19 15 (78.9) 2 (10.5) 2 (10.5)
B. Research B1.a 19 13 (68.4) 3 (15.8) 3 (15.8)
B2.a 19 14 (73.7) 2 (10.5) 3 (15.8)
B3 19 12 (63.2) 5 (26.3) 2 (10.5)
B4 19 2 (10.5) 6 (31.6) 11 (57.9)
C. Progress reports C1.a 18 9 (50.0) 8 (44.4) 1 (5.6)
D. Technical facilities D1 18 15 (83.3) 0 (0.0) 3 (16.7)
D2 18 9 (50.0) 5 (27.8) 4 (22.2)
D3 18 7 (38.9) 4 (22.2) 7 (38.9)
D4 18 1 (5.6) 10 (55.6) 7 (38.9)
E. Ethical implications E1 18 16 (88.9) 1 (5.6) 1 (5.6)
E2 18 13 (72.2) 2 (11.1) 3 (16.7)
F. Education and training F1 18 Pre-graduate 12 (66.7) 1 (5.6) 3 (16.7)
Post-graduate 14 (77.8)
F2.a 18 13 (72.2) 4 (22.2) 1 (5.6)
G. Citizens G1 18 4 (22.2) 10 (55.6) 4 (22.2)
G2 18 8 (44.4) 7 (38.9) 3 (16.7)
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to professionals, 77.8% to researchers, 44.4% to citizens and 33.3%
to patients’ associations (data not shown). These progress reports
were reported as published by universities and government
ministries in an equal number of countries. Only in the UK were
universities, ministries and other institutions (the UK Genetic
Testing Network, UKGTN and the PHG Foundation) listed as
publishing reports. A majority of countries reported that progress
reports were not regularly updated (data not shown).
Section D: technical facilities and
health technology assessment
Fifteen (83.3%) countries (Austria, Belgium, Croatia, Estonia,
Finland, France, Hungary, Italy, Malta, Norway, Poland, Slovenia,
Spain, The Netherlands and the UK) reported that there were
national working groups on the development of policies and/or
services related to genomics in the healthcare, of which half
worked under the umbrella of the National Ministries of Health.
Additionally, 38.9% of the countries (Belgium, France, Italy,
Norway, Slovenia, Spain and the UK) reported working groups on
the development of genomic policies in healthcare at the regional
level (table 2). Nine countries (50%) (Austria, Belgium, Croatia,
France, Hungary, Poland, Spain, The Netherlands and the UK)
documented the presence of national agencies carrying out Health
Technology Assessment (HTA) or horizon scanning on genomic-
based technologies. In two of these countries, HTA or horizon
scanning was performed by the Ministry of Health (data not
shown). Spain was the only country reporting the existence of
regional agencies for genomic HTA (table 2).
Section E: ethical and legal implications of policies
Sixteen (88.9%) countries (Austria, Belgium, Croatia, Estonia,
Finland, France, Hungary, Italy, Malta, Norway, Poland, Portugal,
Slovenia, Spain, The Netherlands and the UK) reported having de-
partments or agencies dealing with ethical issues related to the use of
genomics in public health (table 2), with half of these departments
being part of the Ministry of Health (data not shown). Thirteen
countries (72.2%) (Austria, Belgium, Croatia, Estonia, Finland,
France, Malta, Norway, Poland, Portugal, Slovenia, Spain and The
Netherlands) were aware of the existence of departments and/or
agencies with expertise in engagement in ethical and/or legal
matters in genomics (table 2).
Section F: education and training of
health professionals
Twelve (66.7%) (Croatia, Estonia, Finland, France, Hungary, Italy,
Norway, Poland, Portugal, Slovenia, The Netherlands and the UK)
and fourteen (77.8%) countries (Croatia, Estonia, Finland, France,
Hungary, Italy, Malta, Norway, Poland, Portugal, Slovenia, Spain,
The Netherlands and the UK) reported the presence of pre-graduate
and postgraduate, respectively, university courses on genomics in
healthcare (table 2).
Thirteen (72.2%) states (Austria, Belgium, Croatia, Estonia,
Finland, Hungary, Italy, Malta, Norway, Poland, Slovenia, Spain
and the UK) reported having training courses for health profes-
sionals on the appropriate use of genetic testing for susceptibility
to complex disorders (table 2). All countries reported that these
courses were directed to specialized physicians, 53.8% that they
were aimed at scientists/researchers, 46.2% at the general practi-
tioners and 38.5% at general health professionals (data not shown).
Section G: citizens
The majority of the responding countries (55.6%) reported a lack of
specific information campaigns addressed to citizens (by use of ad-
vertisements on billboards, TV or radio, etc.) on genetic tests of
susceptibility for complex diseases. Only four countries (Estonia,
Poland, Slovenia and Spain) reported having such information
campaigns (table 2).
Lastly, eight (44.4%) countries (Austria, Croatia, Estonia, France,
Latvia, Slovenia, Spain and The Netherlands) reported that they had
adopted a legal framework or professional guidelines on the ethical
implications of direct-to-consumer genetic testing (table 2).
Discussion
This paper summarizes the first attempt to survey the policy
framework of genomics in healthcare across EU member states.
Despite a relatively low response rate of 65.5%, some conclusions
can be drawn from the results.
First, few CMOs reported specific guidelines in place for policies
on genomics in healthcare in their countries, with 12 reporting
having already implemented a policy on genomics in healthcare
and 10 reporting the presence of specific guidelines. A detailed
examination was undertaken of the documents provided; four
Table 3 Answers on the funding support (and related amount) for
the development of genomics in healthcare in the responding
countries
Countries reporting any funding support (N=15) N %
A2.b Public funding 15 100
Public institutions of fundinga
Ministry of Research 6 40.0
Ministry of Health 14 93.3
Other Ministries 3 20.0
Other public institutions 10 66.7
A3. Amount of public fundingb
£50 000 4 26.7
£50 000–200 000 0 0.0
>£200 000 6 40.0
Not aware 5 33.3
A2.b Private funding 5 33.3
Private institutions of fundinga
Pharmaceutical industry 2 40.0
Private research institutions 3 60.0
Other 3 60.0
A4. Amount of private fundingb
£50 000 0 0.0
£50 000–200 000 0 0.0
>£200 000 2 13.3
Not aware 13 86.7
aMultiple-answer questions. Total is >100% as respondents can
select more than one answer.
bFrom the past calendar year, see table 1.
Table 4 Answers on the funding support for the research in policy
or services development in genomics in healthcare in the
responding countries
Countries reporting any funding support (N=14) N %
B2.b Public funding 14 100.0
Public institutions of fundinga
Ministry of Research 3 21.4
Ministry of Health 11 78.6
Other Ministries 3 21.4
Other public institutions 4 28.6
B2.b Private funding 0 0
Private institutions of fundinga
Pharmaceutical industry 0 0.0
Private research institutions 0 0.0
Other 0 0.0
aMultiple answer questions. Total is >100% as respondents can
select more than one answer.
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were recent guidelines on PHG (Belgium, France, Italy and UK),7–11
and the remaining six covered other aspects of genomics and
healthcare (e.g. in vitro regulation directives, prenatal diagnosis,
rare diseases, hereditary tumours and ethical committee).12–20
Most CMOs reported that there was financial support available
for the development of genomic policies, implying a commitment
among some of the countries surveyed to introduce policies where
they do not yet exist. This funding was, in most cases, from public
sources, typically from the Ministry of Health. A few countries
reported additional funding from private institutions, but were
unable to support these claims with reference to external organiza-
tions or supporting documents. Therefore, with the exception of the
United Kingdom (which cites the PHG Foundation and The Genetic
Alliance UK as sources of private funding) it appears that there is a
relative lack of private funding for the development of policies on
genomics in healthcare in the surveyed countries. More progress
should be achieved with particular regard to the involvement of
private foundations (e.g. the PHG foundation for the UK) or
pharma companies while taking into account any bias related to
the contribution of for profit companies.
Concerning the presence of research facilities to support the de-
velopment of policy, these were public in the majority of cases, such
as the ‘‘Inserm: institut the´matique multi organisme (ITMO) Sante´
publique’’ in France, and were also present in countries where
dedicated policies are not yet implemented (Croatia and Slovenia).
Again, all these research institutions received public funding, mainly
from the Ministry of Health.
Half of the responding CMOs reported publication of national
progress reports on genomics in healthcare, although few reported
that such reports are regularly developed. Again by taking a closer
look at the documentation enclosed, those from Belgium and
Austria reported on direct-to-consumer genetic tests, those from
Italy, Norway, Spain, The Netherlands and UK reported on PHG,
while in the remaining countries, the documentation enclosed was
not relevant.
Even though the majority of the responding CMOs reported the
existence at the national level of working groups dedicated to the
development of policies and/or services related to the development
of policies on genomics in healthcare, very few (40%) report having
equivalent groups at the regional level. Only half of respondents
documented the presence of national agencies carrying out HTA
or horizon scanning of genomic-based technologies, with only one
country (Spain) reporting such agencies at the regional level. This
makes Spain the only country reporting the existence of agencies
dedicated to HTA or horizon scanning at both the national21,22 and
the regional level (Andalusian region).23 Some others, like Italy,
reported regional agencies (e.g. in the Veneto, Emilia Romagna,
and Lombardy regions24,25), but none at the national level.
Perhaps, dealing with the previous issue the survey can be affected
by the different historical approach to HTA of each country.
In contrast, a positive finding of the survey is that most countries
appear to have expertise in ethical and legal issues associated with
genomic technologies, although respondents submitted few
supporting documents to back up the claims made. There are
several ethical and legal issues related to the use of genomic-based
technology; for example, those pertaining to sharing of personal
biological samples in order to further genomic research. The
increasing need for such data sharing requires a balance between
protecting individuals from foreseeable harms, such as privacy
breaches, and allowing the full potential of genomic technologies
to be realized.26
The survey highlighted how pre- and post-graduate courses on
genomics in healthcare are now common.27 Many include training
on the appropriate prescription and adequate interpretation of
genetic susceptibility testing for complex disorders.28 These results
are important, as recent evidence suggests that physicians, public
health specialists and health professionals are not sufficiently
prepared to apply genomic knowledge in prevention or treatment
of disease.29–33 The importance of genomics education among
general practitioners and public health specialists has, therefore,
been acknowledged at the European level. Policymakers and educa-
tional institutions should provide incentives for the interdisciplinary
education of healthcare professionals and scientists from the earliest
stages of professional development, in addition to specific training
for healthcare professionals, bioscientists, ICT professionals and
those with expertise in regulatory and social domains to facilitate
collaborative development of the tools for genomic medicine across
Europe. On that direction, interactions between CMOs and
academic institutions through the FEAM and The Association of
Schools of Public Health in the European Region (ASPHER)
should be promoted and implemented.
The results indicate a lack of educational outreach (through ad-
vertisements on billboards, TV or radio, etc.) to general citizens
about genomics. This is an issue that must be approached with
care, given the potential for misleading claims, but it does suggest
that the public may be relatively uninformed about the scope for
genetic screening services. It also introduces the problem of a
possible democratic deficit, which arises when the general
population is uninformed about a topic on which legislation is
made.34
Finally, the results of the survey show that there is a lack of well-
defined frameworks (in the form of legal, ethical and professional
guidelines) addressed to citizens on the appropriate use of direct-to-
consumer genetic tests.35 In this field, both health literacy and
education can play a role in order to prevent the so-called cascade
effect – defined as the ‘‘chain of events initiated by an unnecessary test,
an unexpected result, or patient or physician anxiety, which results in
ill-advised tests or treatments that may cause avoidable adverse effects
and/or morbidity’’,36 which is responsible for unjustified health ex-
penditure, and the advent of unpatients – intended as subject sharing
a genetic predispositions and waiting for the appearance of any
symptoms of illness, while organizing their lives in function of
periodic medical examinations and analysis or even feeling sick
without any diseases or just developing psychosomatic
symptoms.37 As citizens and patients are increasingly taking
advantage of social media and new technologies to participate mean-
ingfully in shared decisions with health professionals about their
clinical care, policy makers should establish mechanisms to
promote health literacy among European citizens, particularly with
regard to direct-to-consumer genetic tests.
The survey is subject to a number of important limitations. First,
the response rate was below 70%, as only 19/29 CMOs actually
responded to the survey. Second, despite three prompts, we did
not receive answers from Cyprus, the Czech Republic, Denmark,
Greece, Luxembourg, Sweden, Bulgaria, Germany, Romania or
Slovakia, and the lack of some large countries could limit the de-
scription of the policy framework of genomic policies in healthcare
across EU. It is likely, in fact, that these countries have national
policies on genomics in place, especially in the case of Central and
Northern EU member states, which have participated in relevant
projects funded by the EC. Third, in a number of cases, the
CMOs were uncertain about the answers (responding with the
answer ‘‘Not Aware/Not Certain’’), meaning that some activities
taking place in university, industry or other organizations could be
unknown to the CMOs and we might have underestimated the
positive or negative answers from this survey. Also, we are not
able to exclude that CMOs asked a second opinion or delegated
another subject in order to answer the questions. There raises the
doubt if CMOs were the appropriate targets to survey such a very
specific topic. However, the CMOs are the most senior advisors on
health matters and the importance of their involvement on the topic
was emphasized during the CMO meeting. Furthermore, the re-
quirement to search and enclose documents or references to
support answers should have stimulated CMOs in undertaking sup-
plementary research on the topic.
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Our study did not aim to evaluate the impact of national policy
on genomics on health outcomes, which will be an important focal
point for future research if meaningful comparisons of policy im-
plementation are to be made across different countries. Recently, a
discussion document published by the PHG Foundation proposes a
new paradigm that looks beyond PHG as it addresses the changing
health needs of populations.38 The document suggests a new
framework for personalised healthcare through which societies
might address the problems of health and current healthcare
systems, where personalization of healthcare is at the centre. The
inclusion of many technologies, alongside genomic technologies,
could increase knowledge about individuals and their health and
disease, particularly including new biomedical and digital
technologies. The development and inclusion of personalised
prevention should become a complementary approach to existing
paradigms of classical public health practice. In the paper, authors
also suggest ways in which the organization of health services and
public policy may need to change and adapt to turn these potentials
into reality and the role that public health leaders should play in
catalyzing these changes.
In conclusion, this survey represents the first attempt to investi-
gate the current state of genomic policy development and imple-
mentation among EU member states (plus Norway). The results
indicate that some countries have more extensive policies and
support structures in place than others. Absence of funding for
policy development in several countries represents a challenge that
should be urgently addressed, particularly by exploring the possibil-
ity of involving the private sector in contributing to funding.
Additionally, even though the vast majority of the respondents
reported having working groups on genomics, there is a lack of
structured information campaigns for citizens on genomics in
general and direct-to-consumer genetic testing in particular.
The results of our survey suggest a need for a co-ordinated effort
to foster the development and further harmonization of dedicated
policies across the EU in order to integrate genomics policies into
existing health systems in a responsible manner. Introducing a
common policy framework on PHG at the EU level could
represent one of the drivers needed to manage a future with increas-
ingly personalized healthcare and a shift in the use of genomic
approaches from disease treatment to prevention.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 This survey represents the first attempt to investigate the
current state of genomic policy development and implemen-
tation among EU member states. Some countries have more
extensive policies and support structures in place than
others.
 Absence of funding for policy development in several
countries represents a challenge that should be urgently
addressed, particularly by exploring the possibility of
involving the private sector in contributing to funding.
 The importance of implementing genomics education
among general practitioners and public health specialists at
the European level has to be highlighted.
 There is a lack of structured information campaigns for
citizens on genomics in general and direct-to-consumer
genetic testing in particular.
 The results suggest a need for a co-ordinated effort to foster
the development and further harmonization of dedicated
policies across the EU in order to integrate genomics
policies into existing health systems in a responsible manner.
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